Basics |
Xencor, Inc.
Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
|
IPO Date: |
December 3, 2013 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$551.57M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.57 | 2.29%
|
Avg Daily Range (30 D): |
$0.31 | 3.35%
|
Avg Daily Range (90 D): |
$0.35 | 3.12%
|
Institutional Daily Volume |
Avg Daily Volume: |
.25M |
Avg Daily Volume (30 D): |
.81M |
Avg Daily Volume (90 D): |
.63M |
Trade Size |
Avg Trade Size (Sh.): |
69 |
Avg Trade Size (Sh.) (30 D): |
69 |
Avg Trade Size (Sh.) (90 D): |
62 |
Institutional Trades |
Total Inst.Trades: |
2,922 |
Avg Inst. Trade: |
$2.01M |
Avg Inst. Trade (30 D): |
$1.35M |
Avg Inst. Trade (90 D): |
$1.55M |
Avg Inst. Trade Volume: |
.07M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$2.27M |
Avg Closing Trade (30 D): |
$1.32M |
Avg Closing Trade (90 D): |
$1.68M |
Avg Closing Volume: |
82.49K |
|
|
|
|
Financials |
|
TTM |
Q1 2025 |
Q3 2024 |
Basic EPS
|
|
$-.66
|
$-.71
|
Diluted EPS
|
|
$-.66
|
$-.71
|
Revenue
|
$
|
$ 32.73M
|
$ 10.71M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$
|
$ -48.63M
|
$ -46.3M
|
Operating Income / Loss
|
$
|
$ -43.18M
|
$ -62.28M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$
|
$ -1.3M
|
$ -1.74M
|
PE Ratio
|
|
|
|
|